Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Estradiol/elcometrine - Population Council/Therapeutics MD

Drug Profile

Estradiol/elcometrine - Population Council/Therapeutics MD

Alternative Names: Annovera; Elcometrine/estradiol ATD™ gel; Estradiol/elcometrine transdermal gel - Antares Pharma/Population Council; Estradiol/elcometrine vaginal ring; NES-E2 CVR; NES/E2; NES/EE/CVR; Nestorone®/estradiol; NestraGel; Segesterone acetate/ethinyl estradiol vaginal ring; Segesterone acetate/ethinyl estradiol vaginal system

Latest Information Update: 09 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Antares Pharma; Population Council (USA)
  • Class Estradiol congeners; Estrenes; Hormonal contraceptives; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered Pregnancy

Most Recent Events

  • 03 May 2019 The label for estradiol/elcometrine has a boxed warning
  • 20 Sep 2018 Estradiol/elcometrine receives market exclusivity as a new chemical entity from the US FDA
  • 29 Aug 2018 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top